<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by Generic product launches, specialty products Rytary & Unithroid, and overall volume growth within Generics and AvKARE segments.
...read full article on Benzinga
